President, I ask unanimous consent that the text of the bill be printed in the Record.  There being no objection, the text of the bill was ordered to be printed in the Record, as follows:                                S. 2103       Be it enacted by the Senate and House of Representatives of      the United States of America in Congress assembled,     SECTION 1. SHORT TITLE.       This Act may be cited as the ``Affordable Insulin Approvals      Now Act''.     SEC. 2. DEEMED APPROVAL UNDER SECTION 351.       Section 7002(e)(4) of the Biologics Price Competition and      Innovation Act of 2009 (Public Law 111-148) is amended--       (1) by striking ``An amended'' and inserting the following:       ``(A) In general.--An amended''; and       (2) by adding at the end the following:       ``(B) Treatment of certain pending applications.--With      respect to an application for an insulin biological product      submitted under subsection (b)(2) or (j) of section 505 of      the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355) with      a filing date that is not later than December 31, 2019, until      the Secretary makes a determination on final approval with      respect to such application, the Secretary shall continue to      review and approve (as appropriate) such application under      such section 505, even if such review and approval process      continues after March 23, 2020. For purposes of completing      the review and approval process for such an application, any      listed drug referenced in the application shall be treated as      a listed drug under section 505(j)(7) of the Federal Food,      Drug, and Cosmetic Act, even if such listed drug is deemed      licensed under section 351 of the Public Health Service Act      during such review and approval process. Effective on the      later of March 23, 2020, or the date of approval under      subsection (c) or (j) of section 505 of the Federal Food,      Drug, and Cosmetic Act of any such application, such approved      application shall be deemed to be a license for the      biological product under section 351 of the Public Health      Service Act.''.                                 ______                                       By 